ASTS: Clinical Assessment of a Motorized Spinal Distraction Rod in the Severe to Early Scoliosis Child

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT03330158
Collaborator
(none)
5
1
1
73.8
0.1

Study Details

Study Description

Brief Summary

The purpose of this biomedical research is to evaluate the feasibility of the treatment with the new spinal distraction device ASTS in patients aged 4 to 10 years with severe early onset scoliosis.

The hypothesis of this project is that the new fully implantable motorized spinal distraction device may provide a correction of scoliosis and progressive elongation ensuring patient comfort and minimizing complications.

The ASTS (for Active Scoliosis Treatment System) growing rod is a new fully implantable motorized spinal distraction device which can ensure a correction of scoliosis and progressive elongation ensuring patient comfort and minimizing complications.

Condition or Disease Intervention/Treatment Phase
  • Device: ASTS
N/A

Detailed Description

Despite a better understanding and technical progress, the evolutionary early scoliosis remains a therapeutic challenge. The definition includes idiopathic scoliosis beginning before the age of 3 years, congenital scoliosis, neuromuscular and syndromic. Spinal deformity is often progressive and may compromise cardiorespiratory function.

The goal of treatment is to prevent further avoiding spinal fusion in a subject in growth. Surgery is indicated in case of failure or cons-indication of conservative treatment (corset or plaster). The principle is to position the posterior rods subcutaneous or in muscle attached to two ends of the deformation.

Intraoperative distraction allows correction of the deformity. A new distraction is performed every 6 months until skeletal maturity.

Considerable complication rates are reported (58%), mainly implant infections and disassembly, because of the need for multiple reoperations. Motorized implants can potentially avoid repeated interventions limiting complications.

Thus, the central hypothesis of this project is a new fully implantable motorized spinal distraction device may provide a correction of scoliosis and progressive elongation ensuring patient comfort and minimizing complications.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
5 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Assessment of a Motorized Spinal Distraction Rod in the Severe to Early Scoliosis Child
Actual Study Start Date :
Feb 5, 2019
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Apr 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: ASTS device

Implantation of device ASTS (for ACTIVE TREATMENT SCOLIOSIS SYSTEM ) in children between 4 and 10

Device: ASTS
Implantation of a motorized spinal distraction rod

Outcome Measures

Primary Outcome Measures

  1. Ability to Implant the device [Day 0: the day of the implantation]

    The surgeon will have to say if the implantation of the device has been done or not

  2. Change of the position of the implant [1 years after the implantation]

    1 year after the implantation of the device, radiographs will be realised to ensure that the implant is still well positioning

  3. Change of the position of the implant [2 years after the implantation]

    2 years after the implantation of the device, radiographs will be realised to ensure that the implant is still weel positioning

  4. Change of the position of the implant [3 years after the implantation]

    3 years after the implantation of the device, radiographs will be realised to ensure that the implant is still weel positioning

  5. Change of the implant's length [3 months, 6 months, 9 months, 1 year, 2 years and 3 years after the implantation]

    The elongation of the implant will be measured in mm on the digital radiography

Secondary Outcome Measures

  1. Post-surgical pain [3 months, after the implantation]

    Self-assessment of pain using a visual analog scale

  2. Post-surgical pain [months after the implantation]

    Self-assessment of pain using a visual analog scale

  3. Post-surgical pain [9 months after the implantation]

    Self-assessment of pain using a visual analog scale

  4. Post-surgical pain [1 year after the implantation]

    Self-assessment of pain using a visual analog scale

  5. Survey to evaluate the quality of life [Day 0]

    Assess quality of life in the questionnaire PedsQL

  6. Survey to evaluate the quality of life [6 months after the implantation]

    Assess quality of life in the questionnaire PedsQL

  7. Survey to evaluate the quality of life [1 year after the implantation]

    Assess quality of life in the questionnaire PedsQL

  8. to ease for the surgeon to implant the device, [Day 0]

    Number of participant with ease for the surgeon to implant the device,

  9. wound closure without tension, [Day 0]

    Number of participant with closure of the wound without tension,

  10. good positioning of the radiographic implant. [Day 0]

    Number participant with good positioning of the radiographic implant.

  11. Number of medical visits [1 year]

    Measure of the number of medical visit in the year after implant

  12. Determine the number of iterative extensions made during follow-up [1 year]

    Number of iterative extensions of 1 year.

  13. correction of deformation immediately after the operation, [3 months, 6 months, 9 month and 1 year]

    Number of participant with correction of deformation immediately after the operation,

  14. correction of deformation immediately after the operation, [3 months after implantation]

    Number of participant with correction of deformation immediately after the operation,

  15. Loss correction at 1 year [6 months after implantation]

    Loss correction at 1 year

  16. Loss correction at 1 year [9 month after implantation]

    Loss correction at 1 year

  17. Loss correction at 1 year [1 year after implantation]

    Loss correction at 1 year

  18. Increase the distance T1-S1 at 1 year [1 year]

    Increase the distance T1-S1 at 1 year (in mm)

  19. Effective Elongation measured on radiographs of specification of the device (in mm) [3 months after implantation]

    Effective Elongation measured on radiographs of specification of the device (in mm)

  20. Effective Elongation measured on radiographs of specification of the device [6 months after implantation]

    Effective Elongation measured on radiographs of specification of the device (in mm)

  21. Effective Elongation measured on radiographs of specification of the device [9 month after implantation]

    Effective Elongation measured on radiographs of specification of the device (in mm)

  22. Effective Elongation measured on radiographs of specification of the device [1 year after implantation]

    Effective Elongation measured on radiographs of specification of the device (in mm)

  23. Nature of complications [1 years]

    describe the nature of complication

  24. Nature of complications [2 years]

    describe the nature of complication

  25. Nature of complications [3 years]

    describe the nature of complication

  26. Nature of complications [5 years]

    describe the nature of complication

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 10 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient 4 to 10 years

  • Patient weight between 15kg at 50kg

  • Introducing severe scoliosis (Cobb angle> 40 °) with early onset

  • Failed or cons-indication of conservative treatment (cast or brace)

  • Agreement of parents or legal guardian (written agreement) and the patient (at least an oral agreement).

Exclusion Criteria:
  • Contraindication to surgery

  • Age less than 4 years or above 10 years

  • Weight less 15kg and above 50 kg

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU de Toulouse Toulouse France 31000

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Franck Accadbled, MD PhD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT03330158
Other Study ID Numbers:
  • RC31/15/7851
First Posted:
Nov 6, 2017
Last Update Posted:
Dec 23, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 23, 2021